Scientists who have been monitoring immune responses to the virus are now starting to see encouraging signs of strong, lasting immunity, even in people who developed only mild symptoms of Covid-19, a flurry of new studies suggests.
Inspired by a unique kind of infection-fighting antibody found in llamas, alpacas, and other camelids, a research team at the University of California, San Francisco, has synthesized a molecule that they say is among the most potent anti-coronavirus compounds tested in a lab to date
While the world is transfixed by the high-stakes race to develop a COVID-19 vaccine, an equally crucial competition is heating up to produce targeted antibodies that could provide an instant immunity boost against the virus.
Sweden’s top health authority says people who have had the novel coronavirus are likely to be immune for at least six months after being infected, whether they’ve developed antibodies or not.
In short, though antibodies have proved invaluable for tracking the spread of the pandemic, they might not have the leading role in immunity that we once thought. If we are going to acquire long-term protection, it looks increasingly like it might have to come from somewhere else.
Below is an updated list of 19 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that they’re effective, most are still at early stages of research. We also included a warning about a few that are just bunk.
“Wait. I can catch Covid twice?” my 50-year-old patient asked in disbelief. It was the beginning of July, and he had just tested positive for SARS-CoV-2, the virus that causes Covid-19, for a second time — three months after a previous infection. While there’s still much we don’t understand about immunity to this new illness, a small but growing number of cases like his suggest the answer is “yes.”
People who have recovered from Covid-19 may lose their immunity to the disease within months, according to research suggesting the virus could reinfect people year after year, like common colds. Blood tests revealed that while 60% of people marshalled a “potent” antibody response at the height of their battle with the virus, only 17% retained the same potency three months later.
Regeneron Pharmaceuticals has started late-stage clinical trials evaluating REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient.
For every person testing positive for antibodies, two were found to have specific T-cells which identify and destroy infected cells. This was seen even in people who had mild or symptomless cases of Covid-19. But it's not yet clear whether this just protects that individual, or if it might also stop them from passing on the infection to others.
The true number of Americans who've been infected with COVID-19 may top 20 million, according to new estimates from the Centers for Disease Control and Prevention. The assessment comes from looking at blood samples across the country for the presence of antibodies to the virus. For every confirmed case of COVID-19, 10 more people had antibodies
While it’s likely people develop some immunity after being infected with the coronavirus, experts still don’t know whether you need a certain amount of antibodies to fight off another infection. And even if you do have the right amount, it also isn’t clear yet how long its protection lasts.
There’s a lot of work being done on antibodies for the coronavirus and on the protein domains they recognize. This of course has bearing both on the idea of monoclonal antibody therapies and for the vaccines that are in development, so let’s have a look at the new data.
In a significant medical breakthrough, Israel's Institute for Biological Research Institute (IIBRI) has wrapped up the development of a potential treatment for the coronavirus disease. The scientists say they have identified an antibody that neutralizes SARS-CoV-2 in vitro or outside of a living organism.